$AMGN Recent News Amgen ends trials of stomach-cancer

New Post Public Reply Private Reply Replies (0) Message Board

Dec 17, 2014 at 11:55 AM

$AMGN Recent News

Amgen ends trials of stomach-cancer therapy 9:57 a.m. Nov. 24, 2014 - Tess Stynes
Amgen's stock drops after trial misses secondary endpoint 9:20 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen's stock drops 2% in premarket trade 9:07 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen study on cancer treatment misses secondary endpoint 9:06 a.m. Nov. 4, 2014 - Tomi Kilgore
Facebook, Gilead shares fall after hours 6:14 p.m. Oct. 28, 2014 - Sue Chang
Amgen, under investor pressure, outlines strategy 10:05 a.m. Oct. 28, 2014 - MarketWatch.com
Amgen's stock rises after company outlines capital allocation plans 9:07 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen's stock climbs 3.2% in premarket trade after capital allocation plans 8:55 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 revenue $20.8 bln-$21.3 bln vs. FactSet consensus $20.33 bln 8:54 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 adj. EPS $9.05-$9.40 vs. FactSet consensus $9.08 8:53 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to payout 60% of adj. earnings to shareholders through 2018 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to raise dividend 30% starting in Q1 2015 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen resumes share buybacks, with plans for $2 bln in repurchases through 2015 8:51 a.m. Oct. 28, 2014 - Tomi Kilgore
‘Dumb money’ unloads bullish oil bets as prices pose threat to stocks 8:35 a.m. Oct. 28, 2014 - Shawn Langlois
4 more ‘Amazon’ stocks you may want to avoid 8:43 p.m. Oct. 27, 2014 - Philip van Doorn
Newscast: Stocks mixed -- barely 6:46 p.m. Oct. 27, 2014 - MarketWatch
Twitter shares drop in wake of quarterly results 5:07 p.m. Oct. 27, 2014 - Sue Chang
Amgen posts strong results on higher sales 4:57 p.m. Oct. 27, 2014 - MarketWatch.com
Updates, advisories and surprises 4:31 p.m. Oct. 27, 2014 - MarketWatch
Amgen net drops, but adjusted earnings beat views 4:14 p.m. Oct. 27, 2014 - Russ Britt

Meet 5 Big Tech Stocks Expected To See Profits Surge 8:03 p.m. Dec. 16, 2014 - Investors Business Daily
Alkermes Starts Phase I Study on Schizophrenia Candidate - Analyst Blog 6:00 p.m. Dec. 16, 2014 - Zacks.com
Acorda's Ampyra in Phase III for Post-Stroke Walking Deficit - Analyst Blog 5:46 p.m. Dec. 16, 2014 - Zacks.com
Is Illumina (ILMN) Worth Adding to Your Portfolio? - Analyst Blog 5:43 p.m. Dec. 16, 2014 - Zacks.com
OPKO Up on Announcing Global Partnership with Pfizer - Analyst Blog 5:00 p.m. Dec. 16, 2014 - Zacks.com
My Strategy For Objective, Emotionless Dividend Growth Investing, Part 4 3:26 p.m. Dec. 16, 2014 - Seeking Alpha
4 Top Ranked Biotech Stocks that Beat the Market in 2014 - Analyst Blog 11:26 a.m. Dec. 16, 2014 - Zacks.com
Stock Market News for December 16, 2014 - Market News 10:10 a.m. Dec. 16, 2014 - Zacks.com
Amgen: Assessing The Split Up Value 10:09 a.m. Dec. 16, 2014 - Seeking Alpha
Early Morning Activity Shows Amgen (AMGN) Down 9:40 a.m. Dec. 16, 2014 - TheStreet.com
Amgen Just Crashed 50% In Premarket, Here's How It Looked 8:55 a.m. Dec. 16, 2014 - benzinga.com
Alexion's Soliris Receives Orphan Drug Status in Japan - Analyst Blog 6:15 p.m. Dec. 15, 2014 - Zacks.com
Jazz Pharmaceuticals Starts Defibrotide Rolling NDA Filing - Analyst Blog 5:50 p.m. Dec. 15, 2014 - Zacks.com
Alnylam Provides Pipeline Update, Growth Strategy - Analyst Blog 5:50 p.m. Dec. 15, 2014 - Zacks.com
Druckenmiller Adds Healthcare Stocks to Portfolio 3:57 p.m. Dec. 15, 2014 - GuruFocus.com
Puma Biotechnology Reveals Positive Interim PB272 Data - Analyst Blog 3:20 p.m. Dec. 15, 2014 - Zacks.com
Backtesting The New Nifty Fifty Using Weighted, Equal-Weight, And Random-Assignment Designs 3:15 p.m. Dec. 15, 2014 - Seeking Alpha
Former Onyx CEO Returns to Biotech to Launch Boston Start Up 9:23 a.m. Dec. 15, 2014 - TheStreet.com
Dividend Challengers: 24 Increases Expected By February 28 3:17 p.m. Dec. 13, 2014 - Seeking Alpha
How Can Drugmakers Handle New Pricing Pressures? 4:38 p.m. Dec. 11, 2014 - Investors Business Daily

Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Pegfilgrastim 10:23 a.m. Today - PR Newswire - PRF
TetraLogic Provides Update on Ovarian Cancer Study 7:01 a.m. Dec. 16, 2014 - GlobeNewswire
Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Dec. 11, 2014 - PR Newswire - PRF
Frequentz Broadens Expertise in Traceability Space with Addition of Lew Kontnik as Strategic Advisor 4:05 p.m. Dec. 10, 2014 - PR Newswire - PRF
Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO™ (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia 9:00 p.m. Dec. 8, 2014 - PR Newswire - PRF
New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) For Advanced Melanoma 4:20 p.m. Dec. 8, 2014 - PR Newswire - PRF
FDA Approves Amgen's XGEVA® (Denosumab) For The Treatment Of Hypercalcemia Of Malignancy Refractory To Bisphosphonate Therapy 9:00 a.m. Dec. 8, 2014 - PR Newswire - PRF
Amarantus Appoints Renowned Drug Development Expert and Co-Founder of Amgen, Joseph Rubinfeld, Ph.D., to Its Board of Directors 8:01 a.m. Dec. 8, 2014 - GlobeNewswire
Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease 1:00 p.m. Dec. 6, 2014 - PR Newswire - PRF
Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma 11:00 a.m. Dec. 6, 2014 - PR Newswire - PRF
Amgen To Webcast Investor Meeting At Upcoming American Society of Hematology (ASH) 56th Annual Meeting And Exposition 7:00 p.m. Dec. 3, 2014 - PR Newswire - PRF
Actress Adamari López And Amgen Launch Spanish-Language Chemotherapy: Myths Or Facts™ Website And Resources 4:30 p.m. Dec. 3, 2014 - PR Newswire - PRF
FDA Approves BLINCYTO™ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia 3:48 p.m. Dec. 3, 2014 - PR Newswire - PRF
Endonovo Therapeutics Receives Final Commissioned Report Recommendations Regarding FDA Regulatory Pathway for Urinary Incontinence Treatment 9:06 a.m. Dec. 2, 2014 - Marketwired
A New Combined Approach to Cancer Immunotherapy is Needed 12:35 p.m. Dec. 1, 2014 - ACCESSWIRE
Personalized Medicine and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment 4:06 p.m. Nov. 27, 2014 - PR Newswire - PRF
Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Nov. 25, 2014 - PR Newswire - PRF
Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer 9:15 a.m. Nov. 24, 2014 - PR Newswire - PRF
Biotech Stocks in Motion - Amgen, Merrimack Pharma, NPS Pharma, BioMarin Pharma, and Regeneron Pharma 8:45 a.m. Nov. 24, 2014 - PR Newswire - PRF
Retrophin Names Margaret Valeur-Jensen, Ph.D. as General Counsel 8:01 a.m. Nov. 19, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Humberto Quintanar Strengthens McKinley Irvin's Seattle Team

Humberto Quintanar Makes His Move In a world where legal battles can shake lives to the core, McKinley Irvin is throwing another heavyweight into the ring. They’ve just pulled in Humberto Quintanar, a guy who knows his way around a courtroom like a cabbie knows a city's backstreets. This isn't just another seat-fillin' lawyer; Quintanar packs years of experience as a...

Approved Oil Secures Long-Term NYC Fuel Terminal Deal

Approved Oil Locks in Future with Sunoco Deal Amidst the contraction of New York City's fuel terminal landscape, securing a consistent lifeline to crucial infrastructure feels like striking gold. Approved Oil just locked down an agreement with Sunoco for a new terminal location that'll last deep into the 2040s, and it's about more than just securing a spot on the...

Columbia Distributing Expands to Alaska: A Growth Move

Alaska's Entry: Columbia's New Frontier When Columbia Distributing dives into a new territory, you know they're serious about growth. This latest move sees them planting their flag in Alaska, finally completing a strategic vision that's been brewing for a while. Four-State Strategy Comes to Fruition The transaction with Republic National Distributing Company (RNDC) is no...

Gildan's Troubling Legal Struggles: Investor Action Alert

Gildan's Bumpy Ride: Legal Woes Unfold Well, folks, seems like Gildan Activewear Inc. (NYSE:GIL) is in for a bumpy ride, and not the kind that makes you feel alive, I tell ya. They've been slapped with a class action lawsuit, and the news ain't pretty. Accusations are flying hot about how they've been playing fast and loose with their financials. The Allegations: Channel...

DropGenie Nets $5M to Boost Functional Biology Reach

DropGenie Scores Big with Fresh Financing Boost Out of the Montreal wilderness, DropGenie is charging forward with a fresh $5 million injection in Seed+ financing. This isn't just loose change; it's a ticket to accelerating their mission of advancing functional biology platforms and beefing up data partnerships. You know, the kind of partnerships that even the suits in...

Skechers Facing Class Action: Investors Urged to Act

Skechers Under Fire: Fraud Allegations Surface Alright, if you've been around the stock block a while, you know these stories can often read like a suspense novel. Plot twist: Skechers U.S.A., Inc. (formerly NYSE: SKX) is now facing some serious accusations. There's a class action lawsuit claiming that some shady dealings went down during the company's $9.4 billion...

Cumberland Pharmaceuticals Eyes NDA for Ifetroban in DMD

Rolling the Dice with Ifetroban There's a buzz in the air around Cumberland Pharmaceuticals as they gear up to tackle one of medicine's stubborn giants, Duchenne muscular dystrophy (DMD). They plan to file a New Drug Application (NDA) with the FDA for ifetroban, aiming to treat the cardiomyopathy plaguing many DMD sufferers. Folks who’ve watched Cumberland (NASDAQ:CPIX)...

Ernesta Expands Southeast Reach with Atlanta Showroom

Ernesta's Southeast Play: The Atlanta Showroom Here's something to turn heads in the world of custom home design—Ernesta has just set up shop in Atlanta, a move that speaks volumes about their ambitions in the Southeast market. This isn't just about selling a few more rugs; it's a calculated step into a region ripe with design potential and a hunger for bespoke home...

Gildan Activewear Faces Major Class Action Lawsuit

Investors Turn Against Gildan Activewear Ever see a freight train barreling down the track? That's what it feels like when a class action lawsuit rears its head against a behemoth like Gildan Activewear Inc. (NYSE: GIL). After years of allegedly pulling the wool over investors' eyes, those same investors are now being called to muster—their chance to lead a charge of...

Bertram Capital Backs MCE's Expansive Growth Vision

A Strategic Move for Bertram Capital Right on the heels of seasoned market moves, Bertram Capital has thrown its support behind Motion & Control Enterprises (MCE). This isn't just another portfolio addition; it's a calculated step into the complex world of industrial distribution, partnering with a company renowned for its prowess in engineered solutions. If you've ever...